Results 221 to 230 of about 58,238 (288)
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Early generational and partisan divides in vaccine acceptance in USA during the COVID-19 pandemic. [PDF]
Alonso G, Kiesel S.
europepmc +1 more source
Developing medication independence: The experience of UK teenagers
Aims There is a progression through childhood from being provided medications by caregivers to having to take responsibility for medications yourself, but little is known about when the transition of adolescents managing medicines begins. The aim of this study was to obtain a cross‐sectional sample of UK adolescents and when they become independent ...
Holly Hutchins +5 more
wiley +1 more source
The Creation of a Systematic Framework to Assess Dog Laws and Their Relationship to Societal Changes in the United Kingdom. [PDF]
Weir SA +3 more
europepmc +1 more source
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić +7 more
wiley +1 more source
A comprehensive dataset of U.S. federal laws (1789-2022). [PDF]
Libgober B.
europepmc +1 more source
Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen +4 more
wiley +1 more source

